NewAmsterdam Pharma Company N.V.

NAMSW ·Healthcare, Drug Manufacturers - General, Netherlands
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022
Assets
Cash & Equivalents $490.0M $771.7M $340.5M
Accounts Receivable
Inventory
Total Current Assets $675.7M $863.4M $346.8M $478.0M
Property, Plant & Equipment $383.0K $242.0K $46.0K $34.0K
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $769.3M $864.6M $347.1M $478.5M
Liabilities
Accounts Payable $9.0M $4.7M $16.9M $11.9M
Total Current Liabilities $85.8M $106.9M $49.9M $36.1M
Long-Term Debt
Total Liabilities $85.9M $107.1M $58.7M $48.4M
Stockholders' Equity
Retained Earnings $-762.4M $-558.6M $-317.0M $-140.0M
Total Stockholders' Equity $683.4M $757.5M $288.4M $430.1M